People on the Move: Dr. Janet Woodcock Joins Every Cure Board of Directors
Every Cure welcomes Dr. Janet Woodcock to its board of directors, leveraging her extensive FDA experience to advance the nonprofit’s mission of repurposing existing drugs for treating rare diseases and improving lives through innovative AI-driven strategies.
October 30, 2024
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Every Cure is a nonprofit organization co-founded by Dr. David Fajgenbaum, Dr. Grant Mitchell, and Tracey Sikora in Philadelphia with one goal in mind. By repurposing drugs for various rare diseases, Every cure sought to reach the most people as fast and cheaply as possible. Every Cure has succeeded thus far, helping to advance 28 repurposed drugs for multiple diseases, improving the lives of 30-30k people. Now looking to the future, Every Cure is using AI to rapidly identify connections across all drugs and all diseases to improve even more lives. Dr. Woodcock is sure to be an asset on the board of directors as Every Cure continues to grow and reach more people.
About Dr. Janet Woodcock
Dr. Woodcock recently completed a long career at The Food and Drug Administration (FDA). She served as Director of the Center for Drug Evaluation and Research for over twenty years in several stretches. Most recently she served as Principal Deputy Commissioner and before that as Acting FDA Commissioner. She held multiple other senior positions at FDA including at the Center for Biologics Evaluation and Research (CBER). She was the therapeutics lead for “Operation Warp Speed” during the COVID-19 pandemic. Her most recent effort was spearheading a major reorganization of the FDA’s foods program and the Office of Regulatory Affairs. Dr. Woodcock completed many major regulatory initiatives during her FDA tenure. She was instrumental in getting the biosimilar legislation enacted and worked to ensure adoption in the clinical community. Additionally, she worked with industry and Congress to bring about the first Generic Drug User Fee Act (GDUFA). After the passage of the legislation, she oversaw an extensive reorganization of the generic drug review program at The Center for Drug Evaluation and Research (CDER), that successfully met the aggressive targets of the legislation and led to eventual reauthorization, with the elimination of backlogs and approval of thousands of generic drugs.
About Every Cure
Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
